Abstract Details

Title Onabotulinumtoxin A improves psychological aspects in chronic migraine patients

Topic Headache

Presentation(s) P3 - Poster Session 3 (12:00 PM-1:00 PM)

Poster/Presentation
Number 7-004

Objective

The aim is to assess the efficacy of OnabotulinumtoxinA on psychological aspects of chronic migraine patients.

Background Chronic migraine affects 5.4% of the Kuwaiti population. It is associated with significant headache-related disability, psychiatric comorbidity, and reduces quality of life. We aimed to assess the efficacy of OnabotulinumtoxinA on psychological aspects of chronic migraine patients.

Design/Methods

113 chronic migraineurs were identified in a tertiary headache center. Eligible patients met International Classification of Headache Disorders disorders-third edition revision criteria for chronic migraine. They received 155 units of Onabotulinumtoxin A quarterly according to the Phase III Research Evaluating Migraine Prophylaxis Therapy Trail protocol. Patients received less than 4 injections cycles were excluded. Quality of life, the seven-item Generalized Anxiety Disorder (GAD-7) scores, the nine-item Patient Health Questionnaire (PHQ9), The Pittsburgh Sleep Quality Index (PSQI) were collected before injection and at last visit. Comparison tests were performed using the independent sample t test to assess the effects of onabotulinumtoxin A on quality of life, symptoms of anxiety, depression, and quality of sleep.

Results This retrospective study included 113 chronic migraine patients, with a mean age of 44.92+9.47years, mean disease duration 12.20 +10.10 years and a mean treatment duration 33.72 +43.14 months. At last visit, most of our cohort showed improvement in quality of life (81%), GAD-7 (81%), PHQ9 (79%), and PSQ1 (76%). The mean score of patient satisfaction was 7.21 +2.21. OnabotulinumtoxinA for CM improved Quality of life significantly (72.92 +17.34 versus103.62 +15.62;P< 0.0001). It was showed with significant reduction in GAD-7 (12.00 +4.40 versus 6.61 +4.40; P< 0.0001); PHQ-9 (17.91 +8.43 versus12.52 +8.77; P< 0.0001) scores and PSQI (12.60 +5.66 versus 6.66 +5.04; P< 0.0001) at last visit.

Conclusions

Prophylactic Onabotulinumtoxin A treatment for CM was associated with significant improvement of quality of life, reduction in symptoms of anxiety and depression, and improved symptoms of poor sleep.

Authors/Disclosures
PRESENTER	No disclosure on file
Samar F. Ahmed, MD	Dr. Ahmed has nothing to disclose.
Ohood Almutairi, MD (KIMS)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Raed Alroughani, MD, FAAN	Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
Jasem Y. Al-Hashel, MD (IBN Sina Hospital, AlSabah Medical Area, Neurology Department)	Dr. Al-Hashel has nothing to disclose.
Doaa Youssry	No disclosure on file

��ɫ��

��ɫ��